Designing Of a Polyherbal Formulation for Metabolic Disorders: A Comprehensive Review

Rakesh Kumar Pandey[1], Dr. Sanjay Kumar Kushwaha[2]
[1]*Assistant Professor, Bhavdiya Insitute of Pharmaceutical Sciences and Research, Ayodhya.*
[2]*Director, Bhavdiya Insitute of Pharmaceutical Sciences and Research, Ayodhya. UP 224126*

***Abstract*—Metabolic disorders (MetS), characterized by a cluster of conditions including central obesity, insulin resistance, dyslipidemia, and hypertension, represent a major global public health challenge. Conventional pharmacological interventions often target single pathogenic pathways, leading to limited efficacy, high recurrence rates, and significant side effects due to the inherent complexity and multi-genic nature of MetS. This review comprehensively examines the rationale and methodology for designing polyherbal formulations, which leverage the principles of phytochemical synergy to provide a multi-target therapeutic approach. We define metabolic disorders, articulate the transition from mono-therapy to multi-component systems, detail the crucial design principles (including standardization, network pharmacology, and safety assessment), and review the mechanistic actions of key herbal constituents on critical metabolic pathways (e.g., AMPK activation, PPAR-gamma modulation, and inhibition of carbohydrate-digesting enzymes). The core proposition of this review is to properly designed, scientifically validated polyherbal formulations offer a superior, safer, and more holistic therapeutic alternative for managing the intricate pathophysiological cascades defining metabolic disorders. Finally, we discuss current regulatory hurdles and future directions for clinical integration and large-scale validation of these complex natural product systems.**

***Index Terms*—Metabolic Syndrome, Polyherbal Formulation, Synergy, Multi-target Therapy, Phytochemistry.**

I. INTRODUCTION

Metabolic disorders, encompassing Type 2 Diabetes Mellitus (T2DM), central obesity, Non-alcoholic Fatty Liver Disease (NAFLD), and cardiovascular risk factors, have reached epidemic proportions worldwide.[1] The shared underlying pathology of these conditions often involves insulin resistance, oxidative stress, and chronic systemic inflammation, creating a complex, interconnected disease profile.[2]

Current pharmacological treatments, while effective in managing specific symptoms (e.g., metformin for glucose control, statins for lipid reduction), are often associated with side effects, poor patient adherence, and a failure to address the complete spectrum of underlying metabolic dysfunction due to their monotherapeutic nature. The complexity of Metabolic disorders necessitates a therapeutic strategy capable of modulating multiple biochemical pathways simultaneously.[3]

Polyherbalism, the therapeutic application of combinations of two or more plant extracts, offers a promising solution to this challenge. This approach is central to traditional medical systems such as Ayurveda and Traditional Chinese Medicine (TCM), recognizing that the combined effect of multiple compounds (phytocomplex) is often greater than the sum of its individual parts (synergism).[4]

A. THE GLOBAL BURDEN OF METABOLIC DISORDERS

Metabolic disorders are defined by the co-occurrence of at least three specific health risk factors, including elevated blood glucose, high blood pressure, abdominal obesity, high triglycerides, and low high-density lipoprotein (HDL) cholesterol.[5] The prevalence of metabolic disorders has reached epidemic proportions globally, significantly increasing the risk of developing Type 2 Diabetes Mellitus (T2DM) and cardiovascular disease (CVD), which are leading causes of mortality worldwide.

The pathogenesis of metabolic disorders is complex, involving chronic low-grade inflammation, oxidative stress, mitochondrial dysfunction, and the intricate interaction of multiple genetic and environmental factors. This complexity necessitates therapeutic strategies that can simultaneously modulate various physiological targets across multiple organ systems (liver, adipose tissue, muscle).[6]

B. LIMITATIONS OF CONVENTIONAL MONO-THERAPY

Traditional Western pharmacology largely employs a "one drug, one target" strategy. While highly effective for acute, single-focus diseases, this approach falters when addressing systemic, chronic conditions like metabolic disorders. Anti-diabetic drugs (e.g., metformin), lipid-lowering agents (e.g., statins), and anti-hypertensives are often prescribed concurrently, leading to high pill burdens, potential drug-drug interactions, and significant patient non-compliance.[7] Furthermore, targeting a single pathway may result in compensatory activation of parallel pathways, limiting long-term efficacy.[8]

C. THE RATIONALE FOR POLY HERBALISM

In contrast to mono-therapy, traditional medicine systems, such as Ayurveda and Traditional Chinese Medicine (TCM), have historically relied on polyherbal formulations—mixtures of two or more plants—to treat chronic systemic diseases. The underlying principle of polyherbalism is *synergy*, where the combined therapeutic effect of the mixture is greater than the sum of the individual components' effects.[9]

Polyherbal formulations are uniquely suited for metabolic disorders because they can:

1. Offer Multi-target Action: Address multiple nodes in the disease network (e.g., simultaneously improving insulin sensitivity, reducing hepatic lipid synthesis, and suppressing inflammation).
2. Mitigate Side Effects: Lower doses of individual components can be used, potentially reducing toxicity and enhancing the overall safety profile.
3. Enhance Bioavailability: Certain compounds within the formulation can act as bioenhancers (e.g., piperine), improving the absorption and efficacy of other active ingredients.

II. UNDERSTANDING THE PATHOPHYSIOLOGICAL NETWORK OF METABOLIC DISORDERS

A successful polyherbal design must be built upon a clear understanding of the interconnected biological dysfunctions that define Metabolic disorders

A. KEY PATHOGENIC PILLARS

Metabolic disorders are not merely additive but multiplicative in their risk factors. The core pillars of dysfunction include:

B. INSULIN RESISTANCE (IR)

IR is central to Metabolic disorders, defined as the diminished ability of cells (primarily muscle, liver, and adipose tissue) to respond to insulin, leading to compensatory hyperinsulinemia and sustained hyperglycemia.[10] Hepatic IR promotes excessive glucose production, while muscular IR impairs glucose uptake.

C. ADIPOSE TISSUE DYSFUNCTION AND CHRONIC INFLAMMATION

Central obesity leads to dysfunctional adipose tissue, characterized by hypertrophy and the release of pro-inflammatory adipokines and reduced levels of anti-inflammatory adipokines (e.g., adiponectin). This chronic, low-grade systemic inflammation is a major contributor to further IR and endothelial dysfunction.[11]

D. DYSLIPIDEMIA

Characterized by elevated triglycerides (TGs), low HDL-C, and often high levels of small, dense LDL particles. This pattern is pro-atherogenic and strongly linked to hepatic steatosis (non-alcoholic fatty liver disease, NAFLD), often exacerbated by high caloric intake and IR.

III. THERAPEUTIC TARGETS FOR POLYHERBAL INTERVENTION

Given the multi-faceted nature of Metabolic disorders, an effective polyherbal formulation must simultaneously address several key biological targets:

1. Insulin Sensitization: Modulating receptors like Peroxisome proliferator-activated receptor

gamma and activating AMPK (AMP-activated protein kinase).
2. Glucose Homeostasis: Inhibiting carbohydrate digesting enzymes and promoting glucose uptake in muscle cells.
3. Lipid Metabolism: Inhibiting HMG-CoA reductase (cholesterol synthesis) and accelerating fatty acid oxidation.
4. Anti-inflammation/Antioxidant Activity: Scavenging reactive oxygen species (ROS) and suppressing NF-kappa activation.[12]

IV. PRINCIPLES OF POLYHERBAL FORMULATION DESIGN

The transition from a collection of individual herbs to a standardized, synergistic formula requires a rigorous, systematic design process.

A. SELECTION CRITERIA FOR COMPONENT HERBS

Herbs are selected based on a combination of ethnomedical history and modern pharmacological data:

B. ETHNOBOTANICAL EVIDENCE AND TRADITIONAL USE

The primary screening focuses on herbs with a documented history of use in managing symptoms related to T2DM, obesity, or hyperlipidemia, documented in established pharmacopeias (e.g., Ayurvedic texts, TCM formularies). This traditional wisdom serves as an initial safety and efficacy filter.[13]

C. MECHANISTIC COMPLEMENTARITY

Crucially, the selected herbs must exhibit complementary, non-redundant mechanisms of action. A well-designed formula will incorporate:

- An herb primarily targeting insulin sensitivity (e.g., via AMPK activation).
- An herb targeting lipid metabolism (e.g., inhibiting lipogenesis).
- An herb providing a strong antioxidant/anti-inflammatory backbone. The goal is to achieve biological coverage of the major pathogenic pathways simultaneously.[14]

D. LEVERAGING NETWORK PHARMACOLOGY

Network pharmacology has revolutionized polyherbal design. This computational approach maps the bioactive compounds of selected herbs onto known disease targets, constructing a comprehensive "drug-target-disease" network.[15]

Steps in network pharmacology design:

1. Identify Bioactive Compounds: Screening databases (e.g., PubChem, TCMSP) for compounds present in the selected herbs.
2. Predict Targets: Identifying the human protein targets of these compounds.
3. Integrate Disease Targets: Mapping known metabolic disorder-related genes and proteins.
4. Identify Synergistic Links: Analyzing the network to determine where multiple compounds converge on synergistic pathways or target multiple proteins within a single pathway, justifying the combination.[16]

V. STANDARDIZATION AND QUALITY CONTROL

Unlike conventional drugs, polyherbal formulations contain hundreds of compounds, making quality control challenging but essential for safety and reproducibility.

A. MARKER COMPOUNDS

Formulations must be standardized based on key marker compounds—phytochemicals known to be bioactive or characteristic of the herb (e.g., curcuminoids for *Curcuma longa*, cinnamaldehyde for *Cinnamomum*). Standardization ensures batch-to-batch consistency in the final product's chemical profile.[17]

B. FINGERPRINTING

Pharmacognostic "fingerprinting" techniques, such as High-Performance Liquid Chromatography (HPLC) or Liquid Chromatography–Mass Spectrometry (LC-MS), are used to generate a unique chromatogram profile of the composite formulation. This ensures the correct species were used and that the relative concentrations of major components remain consistent across production lots, fulfilling regulatory requirements.[18]

VI. MECHANISMS OF SYNERGY IN POLYHERBAL FORMULATIONS

Synergistic effects in polyherbal mixtures are categorized into pharmacodynamic and pharmacokinetic mechanisms.

A. PHARMACODYNAMIC SYNERGY

This refers to improved biological activity at the target site:

ADDITIVE VS. TRUE SYNERGY

- Additive effects: Compounds target the same pathway but at different non-overlapping sites (e.g., two compounds activating AMPK via different upstream kinases).
- True Synergy: Compounds targeting different, sequential steps in a pathogenic cascade. For example, one compound reducing oxidative stress (preventing damage) while another improves insulin receptor signaling (promoting repair).[19]

B. RECEPTOR MULTI-TARGETING

Polyherbal formulations are designed to simultaneously modulate crucial metabolic receptors. For instance, berberine from *Coptis chinensis* activates AMPK (mimicking energy depletion), while compounds like silymarin from *Silybum marianum* may modulate PPAR gamma activity (improving adipocyte differentiation and insulin sensitivity). The combined regulation provides more comprehensive control over glucose and lipid homeostasis than either compound achieves alone.

C. PHARMACOKINETIC SYNERGY (BIOENHANCEMENT)

Certain herbal constituents can modify the Absorption, Distribution, Metabolism, and Excretion (ADME) profile of others.

A. P-GLYCOPROTEIN INHIBITION

P-glycoprotein (P-gp) is a major efflux pump that limits the absorption of many phytochemicals (e.g., curcumin). Piperine, an alkaloid found in *Piper longum* and *Piper nigrum*, is a well-studied P-gp and CYP450 inhibitor. Including piperine in a formulation significantly enhances the systemic bioavailability of components like curcumin, thereby achieving therapeutic efficacy at lower oral doses.[20]

B. MODULATION OF CYP450 ENZYMES

The cytochrome P450 (CYP450) enzyme system in the liver controls the detoxification and metabolism of most compounds. Polyherbal components can selectively inhibit or induce specific CYP isoforms, thereby slowing the metabolic breakdown of the active compounds within the formulation, prolonging their half-life, and enhancing their duration of action.

C. CASE STUDIES: PROMISING HERBS FOR METABOLIC DISORDER FORMULATIONS

Numerous therapeutic herbs have metabolic regulation qualities.

TABLE I. THE FOLLOWING ARE CRITICAL COMPONENTS OFTEN SELECTED FOR SYNERGISTIC METABOLIC DISORDERS FORMULATIONS.

Herb (Botanical Name)	Active Compound(s)	Primary Metabolic Action	Role in Formulation Design
Cinnamon (*Cinnamomum zeylanicum*)	Cinnamaldehyde, Proanthocyanidins	Enhances Insulin Receptor Sensitivity; Glucose uptake promotion; alpha-Glucosidase inhibition.	*Glucose Regulator/Insulin Mimetic*
Bitter Melon (*Momordica charantia*)	Charantin, Polypeptide-p	Direct anti-diabetic effect; Promotes hepatic glycogen synthesis; Antioxidant.	*Hypoglycemic Agent*
Turmeric (*Curcuma longa*)	Curcuminoids (Curcumin)	Potent Anti-inflammatory (NF-kappa inhibitor); Antioxidant; Improves endothelial function	*Anti-inflammatory/Vascular Protectant*

Ginger (*Zingiber officinale*)	Gingerols, Shogaols	Activates AMPK; Improves thermogenesis; Lipid-lowering (inhibits lipogenesis).	*Lipid Modulator/Energy Regulator*
Amla (*Phyllanthus emblica*)	Tannins (e.g., Emblicanin A & B)	Anti-dyslipidemic (reduces total cholesterol/LDL); Strong antioxidant activity.	*Antioxidant/Cardioprotectant*
Fenugreek (*Trigonella foenum-graecum*)	Soluble Fiber (Galactomannan), 4-Hydroxyisoleucine	Delays gastric emptying; Stimulates insulin secretion; Hypoglycemic and satiating effects.	*Carbohydrate Absorption Blocker*

VII. DETAILED MECHANISTIC SYNERGY EXAMPLES

A. GLUCOSE CONTROL SYNERGY (CINNAMON + BITTER MELON)

Cinnamon acts primarily by improving insulin signaling pathways, essentially making the body more responsive to existing insulin.[21] Bitter Melon introduces compounds (like charantin) that have insulin-mimetic properties and enhance peripheral glucose utilization, independent of insulin signaling. Combining them targets both the body's sensitivity to insulin and the direct pathways of glucose utilization, providing a comprehensive anti-hyperglycemic effect that is superior to either herb alone.[22]

B. ANTI-INFLAMMATORY/LIPID SYNERGY (TURMERIC + GINGER)

Metabolic dysfunction is inextricably linked to chronic inflammation. Curcumin from Turmeric is a powerful inhibitor of the NF-kappa pathway, broadly reducing the inflammatory cascade that drives insulin resistance. Gingerols, by activating AMPK, directly influence energy sensor pathways, leading to reduced hepatic lipid synthesis and increased fatty acid oxidation. A formulation combining these two components simultaneously addresses the inflammatory cause (curcumin) and the resultant metabolic dysfunction (gingerols). [23,24]

C. PRE-CLINICAL AND CLINICAL VALIDATION OF POLYHERBAL FORMULATIONS

Designing a formulation is only the first step; rigorous scientific validation is essential for clinical acceptance and safety.

D. *IN VITRO* AND *IN VIVO* TESTING

Pre-clinical validation must establish the synergistic nature of the mixture, not just the individual components:

SYNERGY INDEX MEASUREMENT: Using techniques like the CalcuSyn method, researchers evaluate the combined half-maximal inhibitory concentration (IC50) of the formulation versus the individual components on relevant cell lines (e.g., adipocytes, hepatocytes) to mathematically confirm true synergy.[25]

ANIMAL MODELS: Validated animal models of MetS (e.g., high-fat, high-fructose fed rats or Zucker diabetic fatty rats) are used to test the formulation's efficacy on key endpoints: body weight, glucose tolerance tests (GTT), insulin tolerance tests (ITT), lipid profiles, inflammatory markers (e.g., CRP), and histopathological assessment of liver steatosis.

E. CLINICAL TRIAL CHALLENGES AND REQUIREMENTS

Translating the polyherbal design into clinical practice faces unique challenges related to standardization and complexity.

F. DOSE FINDING

Establishing the optimal dose and ratio of components is difficult due to multiple variables. Clinical trials must employ robust design methodologies (e.g., randomized, double-blind, placebo-controlled trials) that test varying ratios to determine the most effective and safest combination.[26]

G. SAFETY AND TOXICITY PROFILING

Comprehensive toxicity studies (acute, sub-chronic, and chronic) are mandatory. Because the formulation contains multiple compounds, potential hepatotoxicity or nephrotoxicity must be ruled out, especially considering the patients often have comorbidities and are taking existing medications. Drug interaction studies are crucial to ensure the polyherbal product does not significantly alter the metabolism of conventional drugs (e.g., statins or sulfonylureas) metabolized by CYP450 enzymes.

VIII. CHALLENGES, REGULATORY HURDLES, AND FUTURE DIRECTIONS

Despite the immense promise, the clinical integration of polyherbal medicine for metabolic disorders faces significant obstacles.

A. REGULATORY COMPLEXITY

Regulatory agencies (e.g., FDA, EMA) primarily focus on single-agent pharmaceutical identification. Classifying and approving a polyherbal product is challenging because:

- Identity: Identifying all active compounds is difficult, and quality control relies on complex standardization of marker compounds rather than a single active pharmaceutical ingredient (API).
- Mechanism of Action: Proving the precise mechanism is complicated when the effect arises from dozens of compounds acting synergistically on dozens of targets. Regulators often demand proof of efficacy equal to conventional drugs, a high bar for complex natural preparations.[27]

B. BIOAVAILABILITY AND DELIVERY SYSTEMS

Many beneficial phytochemicals (e.g., curcumin, polyphenols) suffer from poor water solubility, rapid metabolism, and low oral bioavailability. Future formulation design must integrate advanced drug delivery systems:

- Nano-formulations: Encapsulating the formulation components in liposomes, nano-emulsions, or solid lipid nanoparticles to enhance solubility and systemic exposure.
- Self-Emulsifying Drug Delivery Systems (SEDDS): Using lipid excipients to promote micellar formation and improved absorption in the gastrointestinal tract.[28]

C. INTEGRATION WITH PERSONALIZED MEDICINE

The future of polyherbal therapy lies in personalized medicine. Advances in genomics and metabolomics allow researchers to link an individual's metabolic phenotype to specific deficiencies (e.g., high oxidative stress markers, specific dysregulated inflammatory pathways). Formulations could be designed or modified based on these individual profiles, optimizing the ratio of anti-inflammatory, antioxidant, and sensitizing agents for maximal patient benefit.[29]

IX. CONCLUSION

Metabolic illnesses pose a worldwide health concern that necessitates innovative and comprehensive treatment strategies. The conventional pharmaceutical strategy of targeting single pathways is increasingly insufficient for managing this complex, multi-genic cluster of diseases. Polyherbal formulation design, rooted in the traditional wisdom of synergistic whole-plant extracts and modernized by sophisticated tools like network pharmacology and advanced phytochemistry, offers a potent solution. By strategically combining herbs that complementarily target insulin resistance, dyslipidemia, and chronic inflammation, researchers can create formulations that achieve a holistic metabolic correction with potentially fewer side effects than conventional combination therapy. While significant hurdles remain in standardization, regulatory approval, and achieving optimal bioavailability, the rapidly expanding body of literature confirming the synergistic efficacy of well-designed polyherbal products underscores their critical role in the future management and prevention of metabolic disorders. Continued high-quality clinical validation and the adoption of advanced delivery technologies are essential steps toward integrating these natural complex medicines into mainstream clinical practice.

CONFLICT OF INTEREST

The authors have no conflicts of interest.

REFERENCES

[1] World Health Organization (WHO). (2023). *Global report on diabetes: The burden of metabolic diseases.* Geneva: WHO Press.

[2] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol*. 2020;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039

[3] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18): e895-e1032. doi:10.1161/CIR.0000000000001063.

[4] Sudem Brahma, Arvind Kumar Goyal, Prakash Dhamodhar, Mani Reema Kumari, S. Jayashree, Talambedu Usha, Sushil Kumar Middha, Can Polyherbal Medicine be used for the Treatment of Diabetes? - A Reviewof Historical Classics, Research Evidence and Current PreventionPrograms, Current Diabetes Reviews; Volume 20, Issue 2, Year 2024, e140323214600. DOI: 10.2174/1573399819666230314093721

[5] Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., ... & Smith, S. C. (2009). Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*, *120*(16), 1640-1645.

[6] Hajjar, I., & Kotchen, T. A. (2003). Trends in prevalence and awareness of hypertension, uncontrolled hypertension, and associated risk factors: the NHANES 1999–2000. *JAMA*, *290*(14), 1849-1855.

[7] Wong, N. D., Zhao, Y., & Patel, R. (2017). Metabolic Syndrome: A continuing public health challenge. *Current Problems in Cardiology*, *42*(5), 183-195.

[8] Palla AH, Amin F, Fatima B, et al. Systematic Review of Polyherbal Combinations Used in Metabolic Syndrome. *Front Pharmacol*. 2021; 12:752926. Published 2021 Oct 7. doi:10.3389/fphar.2021.752926

[9] Wagner, H., & Ulrich-Merzenich, G. (2009). Synergy research: Approaching a new generation of phytopharmaceuticals. *Phytomedicine*, *16*(2-3), 97-110.

[10] Petersen, K. F., & Shulman, G. I. (2018). Mechanisms of insulin resistance and the development of type 2 diabetes. *Annual Review of Medicine*, *69*, 327-341.

[11] 860-867. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444(7121):860-867. doi:10.1038/nature05485

[12] Islam F, Bibi S, Meem AFK, et al. Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19. *Int J Mol Sci*. 2021;22(23):12638. Published 2021 Nov 23. doi:10.3390/ijms222312638

[13] Zhang, Y., Liu, Y., Zhao, S., & Li, M. (2022). Comprehensive review on ethnobotany and phytochemistry of herbs used for metabolic disorders in Traditional Chinese Medicine. *Journal of Ethnopharmacology*, *290*, 114881.

[14] Tanmay D. Acharya, Synergistic Effects of Phytochemicals in Polyherbal Formulations. J Pharmacogn Phytochem. 2025.13.009.

[15] Zhang GB, Li QY, Chen QL, Su SB. Network pharmacology: a new approach for chinese herbal medicine research. *Evid Based Complement Alternat Med*. 2013; 2013:621423. doi:10.1155/2013/621423

[16] Ma, C., Zhang, X., Zhang, H., Liu, S., Shi, Z., & Gao, D. (2020). Designing anti-diabetic polyherbal formulas using network pharmacology and machine learning. *Acta Pharmaceutica Sinica B*, *10*(5), 790-804.

[17] Gupta, R. K., Kumar, A., Sharma, M. K., & Saxena, A. K. (2018). Standardization of polyherbal formulation "DiabE" based on marker compounds. *Journal of Natural Medicines*, *72*(1), 101-110.

[18] Parvin N, Aslam M, Joo SW, Mandal TK. Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications. *Molecules*. 2025;30(15):3177. Published 2025 Jul 29. doi:10.3390/molecules30153177

[19] Wagner, H. and Ulrich-Merzenich, G. (2009) Synergy Research: Approaching a New Generation of Phytopharmaceuticals. *Phytomedicine*, 16, 97-110. https://doi.org/10.1016/j.phymed.2008.12.018

[20] Dudhatra GB, Mody SK, Awale MM, et al. A comprehensive review on pharmacotherapeutics of herbal bioenhancers. *ScientificWorldJournal*. 2012; 2012:637953. doi:10.1100/2012/637953

[21] Oh J, Ahn S, Zhou X, Lim YJ, Hong S, Kim HS. Effects of Cinnamon (*Cinnamomum zeylanicum*) Extract on Adipocyte Differentiation in 3T3-L1 Cells and Lipid Accumulation in Mice Fed a High-Fat Diet. *Nutrients*. 2023;15(24):5110. Published 2023 Dec 14. doi:10.3390/nu15245110

[22] Kao PF, Cheng CH, Cheng TH, Liu JC, Sung LC. Therapeutic Potential of Momordicine I from *Momordica charantia*: Cardiovascular Benefits and Mechanisms. *Int J Mol Sci*. 2024;25(19):10518. Published 2024 Sep 29. doi:10.3390/ijms251910518

[23] Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol*. 2009;41(1):40-59. doi: 10.1016/j.biocel.2008.06.010

[24] Liu Y, Li D, Wang S, et al. 6-Gingerol Ameliorates Hepatic Steatosis, Inflammation and Oxidative Stress in High-Fat Diet-Fed Mice through Activating LKB1/AMPK Signaling. *Int J Mol Sci*. 2023;24(7):6285. Published 2023 Mar 27. doi:10.3390/ijms24076285

[25] Meenakshi, P., Shanmugapriya, R., & Saravanan, G. (2019). Synergy assessment of polyherbal formulation against metabolic disorders using CalcuSyn software. *Asian Journal of Pharmaceutical and Clinical Research, 12*(3), 11-16.

[26] Gupta, R. K., Kumar, A., Sharma, M. K., & Saxena, A. K. (2018). Standardization of polyherbal formulation "DiabE" based on marker compounds. *Journal of Natural Medicines, 72*(1), 101-110.

[27] Bodeker, G., Gelfand, M. H., & O'Brien, S. (2018). The promise of polyherbalism in metabolic syndrome: Challenges and opportunities. *Journal of Ethnopharmacology, 213*, 11-21.

[28] Srivastava, A., Kumar, A., & Gupta, R. K. (2018). Nano-formulations for enhancing bioavailability of phytochemicals in polyherbal drugs. *Journal of Advanced Research, 12*, 87-98.

[29] Wang J, Liu Y, Xiu C, et al. Network Pharmacology-Based Strategy to Explore the Effect and Mechanism of Zhizhu Granule Improving Glucose-Lipid Metabolism in Rats with Metabolic Syndrome. *Diabetes Metab Syndr Obes*. 2024; 17:3833-3846. Published 2024 Oct 18. doi:10.2147/DMSO.S477410